Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)



Status:Completed
Conditions:Neurology, Psychiatric, ADHD
Therapuetic Areas:Neurology, Psychiatry / Psychology, Other
Healthy:No
Age Range:6 - 17
Updated:12/21/2018
Start Date:June 18, 2015
End Date:February 16, 2016

Use our guide to learn which trials are right for you!

A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)

The study is designed to evaluate the efficacy and safety of SHP465 in the treatment of ADHD
in children and adolescents (aged 6-17 years). The primary objective of this study is to
evaluate the efficacy of SHP465 administered as a daily morning dose compared to placebo in
the treatment of children and adolescents (6-17 years of age inclusive) diagnosed with ADHD.


Inclusion Criteria:

1. Subject must be 6-17 years of age, inclusive, at the time of consent.

2. Subject's parent or legally authorized representative (LAR) must provide signature of
informed consent, and there must be documentation of assent (if applicable) by the
subject indicating that the subject is aware of the investigational nature of the
study and the required procedures and restrictions in accordance with the ICH GCP
Guideline E6 (1996) and applicable regulations before completing any study-related
procedures.

3. Subject and parent/LAR are willing and able to comply with all of the testing and
requirements defined in the protocol, including oversight of morning dosing.
Specifically, the parent/LAR must be available at approximately 7:00AM (±2 hours) to
dispense the dose of investigational product for the study duration.

4. Subject, who is a female and of child-bearing potential, must not have a positive
serum beta human chorionic gonadotropin pregnancy test at the Screening Visit (Visit
1) and must have a negative urine pregnancy test at the Baseline Visit (Visit 2) and
agree to comply with any applicable contraceptive requirements of the protocol.

5. Subject must have a satisfactory medical assessment with no clinically significant or
relevant abnormalities.

6. Subject meets DSM-IV-TR criteria for a primary diagnosis of ADHD based on a detailed
psychiatric evaluation.

7. Subject has an ADHD-RS-IV Total Score >28 at the Baseline Visit (Visit 2).

8. Subject is functioning at an age-appropriate level intellectually, as determined by
the study Investigator.

9. Subject is currently not on ADHD therapy, or is not completely satisfied with any
aspect of their current ADHD therapy.

10. Subject is able to swallow a capsule whole.

Exclusion Criteria:

1. Subject has a current, controlled (with medications prohibited in this study) or
uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as any
significant comorbid Axis II disorder or significant Axis I disorder (such as
post-traumatic stress disorder, psychosis, bipolar illness, pervasive developmental
disorder, severe obsessive compulsive disorder, depressive or anxiety disorder) or
other symptomatic manifestations that, in the opinion of the examining clinician, will
contraindicate treatment with SHP465 or confound efficacy or safety assessments.
Comorbid psychiatric diagnoses will be established with the Screening Visit (Visit 1)
interview of the K-SADS-PL and additional modules if warranted by the results of the
initial interview. Subjects may continue participation in a behavioral modification
program during the study as long as they have been participating in the program for at
least 1 month at the time of the Baseline Visit (Visit 2).

2. Subject meets DSM-IV-TR diagnosis of conduct disorder. Oppositional defiant disorder
is not exclusionary.

3. Subject is considered a suicide risk in the opinion of the Investigator, has
previously made a suicide attempt, or is currently demonstrating active suicidal
ideation. Subjects with intermittent passive suicidal ideation are not necessarily
excluded based on the assessment of the Investigator.

4. Subject is underweight based on Centers for Disease Control and Prevention body mass
index (BMI)-for-age sex-specific values at the Screening Visit (Visit 1). Underweight
is defined as a BMI <3rd percentile

5. Subject is significantly overweight based on Centers for Disease Control and
Prevention BMI-for-age sex specific values at the Screening Visit (Visit 1).
Significantly overweight is defined as a BMI >97th percentile for this study

6. Subject has a concurrent chronic or acute illness (such as severe allergic rhinitis or
an infectious process requiring antibiotics), disability, or other condition that
might confound the results of safety assessments conducted in the study or that might
increase risk to the subject. Similarly, the subject will be excluded if he or she has
any additional condition(s) that, in the Investigator's opinion, would prohibit the
subject from completing the study or would not be in the best interest of the subject.
The additional conditions would include any significant illness or unstable medical
condition that could lead to difficulty complying with the protocol. Mild, stable
asthma is not exclusionary.

7. Subject has a history of seizure (other than infantile febrile seizures), a chronic or
current tic disorder, or a current diagnosis of Tourette's Disorder. Subject has a
history of tics that are judged by the Investigator to be exclusionary.

8. Subject's blood pressure measurements exceed the 90th percentile for age, sex, and
height (based on the Blood Pressure Levels by Age and Height Percentile [for boys and
girls]) at the Screening Visit (Visit 1) and the Baseline Visit (Visit 2)

9. Subject has a known history of hypertension

10. Subject has a known history of symptomatic cardiovascular disease, advanced
arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm
abnormalities, coronary artery disease, or other serious cardiac problems that may
place him/her at increased vulnerability to the sympathomimetic effects of a stimulant
medication.

11. Subject has a known family history of sudden cardiac death or ventricular arrhythmia.

12. Subject has any clinically significant ECG or clinically significant laboratory
abnormality at the Screening Visit (Visit 1).

13. Subject has current abnormal thyroid function, defined as abnormal thyroid stimulating
hormone and thyroxine at the Screening Visit (Visit 1). Treatment with a stable dose
of thyroid medication for at least 3 months is permitted.

14. Subject has a documented allergy, hypersensitivity, or intolerance to amphetamine or
to any excipients in the investigational product.

15. Subject has failed to respond, based on Investigator judgment, to an adequate
course(s) (dose and duration) of amphetamine therapy

16. Subject has a history of suspected substance abuse or dependence disorder (excluding
nicotine) in accordance with DSM-IV-TR criteria. Subjects with a lifetime history of
amphetamine, cocaine, or other stimulant abuse and/or dependence will be excluded.

17. Subject has a positive urine drug result at the Screening Visit (Visit 1) (with the
exception of subject's current stimulant therapy, if any) or the Baseline Visit (Visit
2), if repeated unless the Investigator can verify that the positive result at the
Screening Visit (Visit 1) is attributed to medication that has been prescribed to the
subject and will be discontinued prior to the Baseline Visit (Visit 2). A positive
result at the Screening Visit (Visit 1) attributed to a prescribed medication requires
a re-test and a negative result at the Baseline Visit (Visit 2) to confirm subject
eligibility.

18. Subject has taken another investigational product or has taken part in a clinical
study within 30 days prior to the Screening Visit (Visit 1).

19. Subject has previously completed, discontinued, or was withdrawn from this study.

20. Subject is taking any medication that is excluded or has not been appropriately washed
out according to the protocol requirements.

21. Subject is required to take or anticipates the need to take medications that have
central nervous system effects or affect performance, such as sedating antihistamines
and decongestant sympathomimetics, or are monoamine oxidase inhibitors. Stable use of
bronchodilator inhalers is not exclusionary.

22. Subject is female and is pregnant or lactating
We found this trial at
36
sites
6141 Sunset Dr # 301
South Miami, Florida 33143
(305) 598-3125
Miami Research Associates Miami Research Associates (MRA) is the largest privately-owned multi-specialty clinical research center...
?
mi
from
South Miami, FL
Click here to add this to my saved trials
400 Bald Hill Road
Warwick, Rhode Island 02886
401-739-9350
?
mi
from
Warwick, RI
Click here to add this to my saved trials
5601 Corporate Way
West Palm Beach, Florida 33407
561-238-3036
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Barnwell, South Carolina 29812
?
mi
from
Barnwell, SC
Click here to add this to my saved trials
8043 Cooper Creek Boulevard Suite 107
Bradenton, Florida 34201
(941) 747-7900
Florida Clinical Research Center, LLC Led by Andrew J. Cutler, M.D., Florida Clinical Research Center,...
?
mi
from
Bradenton, FL
Click here to add this to my saved trials
Colorado Springs, Colorado 80910
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Dallas, Texas 75231
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Dayton, OH
Click here to add this to my saved trials
Dothan, Alabama 36303
?
mi
from
Dothan, AL
Click here to add this to my saved trials
Gainesville, Florida 32607
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
Houston, Texas 77024
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 17115
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77098
?
mi
from
Houston, TX
Click here to add this to my saved trials
Jacksonville, Florida 32216
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Kirkland, Washington 98033
?
mi
from
Kirkland, WA
Click here to add this to my saved trials
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Libertyville, Illinois 60048
?
mi
from
Libertyville, IL
Click here to add this to my saved trials
Lubbock, Texas 79423
?
mi
from
Lubbock, TX
Click here to add this to my saved trials
Marietta, Georgia 30060
?
mi
from
Marietta, GA
Click here to add this to my saved trials
Memphis, Tennessee 38119
?
mi
from
Memphis, TN
Click here to add this to my saved trials
Mount Pleasant, South Carolina 29464
?
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
Naperville, Illinois 60563
?
mi
from
Naperville, IL
Click here to add this to my saved trials
New Orleans, Louisiana 70114
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
O'Fallon, Missouri 63368
?
mi
from
O'Fallon, MO
Click here to add this to my saved trials
Orange, California 92868
?
mi
from
Orange, CA
Click here to add this to my saved trials
Orange City, Florida 32763
?
mi
from
Orange City, FL
Click here to add this to my saved trials
Orlando, Florida 32806
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Overland Park, Kansas 66211
?
mi
from
Overland Park, KS
Click here to add this to my saved trials
Plano, Texas 75093
?
mi
from
Plano, TX
Click here to add this to my saved trials
Rochester Hills, Michigan 48307
?
mi
from
Rochester Hills, MI
Click here to add this to my saved trials
4801 Weldon Spring Parkway
Saint Charles, Missouri 63304
?
mi
from
Saint Charles, MO
Click here to add this to my saved trials
?
mi
from
Salem, OR
Click here to add this to my saved trials
San Diego, California 92108
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Spring Valley, California 91978
?
mi
from
Spring Valley, CA
Click here to add this to my saved trials
Tulsa, Oklahoma 74104
?
mi
from
Tulsa, OK
Click here to add this to my saved trials
Wildomar, California 92595
?
mi
from
Wildomar, CA
Click here to add this to my saved trials